Novo Nordisk Inks $2.6B Deal for Hengrui's Oral Obesity Drug
NVO is trading near its 52-week low of $35.12 (10% above the low).
Summary
Novo Nordisk is paying $300M upfront and up to $2.6B total for global rights (ex-China) to Hengrui's HRS-1596, a phase 1-ready oral GLP-1/GIP dual agonist for obesity and diabetes. This is a significant pipeline addition in the oral obesity space, where Novo already has a strong oral semaglutide franchise. The deal follows recent partnerships with Orbis Medicine ($1.4B) and Nanexa ($1.3B), showing an aggressive external innovation strategy. The transaction is expected to close in Q4 2026, pending antitrust clearance. Watch for phase 1 data readouts and any competitive response from Eli Lilly's orforglipron.
At the time of this announcement, NVO was trading at $38.72 on NYSE in the Life Sciences sector, with a market capitalization of approximately $170.5B. The 52-week trading range was $35.12 to $64.16. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.